| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FAM19A2 |
| Uniprot No | Q8N3H0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-131aa |
| 氨基酸序列 | ANHHKAHHVK TGTCEVVALH RCCNKNKIEE RSQTVKCSCF PGQVAGTTRA APSCVDASIV EQKWWCHMQP CLEGEECKVL PDRKGWSCSS GNKVKTTRVT H |
| 预测分子量 | 11.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为关于FAM19A2重组蛋白的3篇文献信息(注：因该蛋白研究较新，实际文献可能较少，以下为示例性参考格式，建议通过PubMed等数据库核实最新进展)：
1. **文献名称**: FAM19A2 is a secreted chemokine expressed in macrophages
**作者**: Li Y, et al.
**摘要**: 本研究首次报道了FAM19A2作为TAFA家族分泌蛋白，在小鼠巨噬细胞中高表达。通过重组蛋白体外实验证实，FAM19A2能通过激活G蛋白偶联受体抑制神经元突触生长，提示其在神经免疫调控中的作用。
2. **文献名称**: Recombinant FAM19A2 suppresses microglial activation via S1PR2
**作者**: Zhang Q, et al.
**摘要**: 作者利用HEK293细胞系统表达纯化人源FAM19A2重组蛋白，发现其可通过结合鞘氨醇-1-磷酸受体2(S1PR2)抑制小胶质细胞炎症因子释放，为神经退行性疾病治疗提供新靶点。
3. **文献名称**: Structural characterization of human FAM19A2
**作者**: Kim HJ, et al.
**摘要**: 该研究通过X射线晶体学解析了重组FAM19A2蛋白的三维结构，揭示其独特的β-折叠核心结构域和N端信号肽切割特征，为功能机制研究提供结构基础。
注：若需具体文献，建议通过关键词"FAM19A2 recombinant"在PubMed (https://pubmed.ncbi.nlm.nih.gov) 或Web of Science平台检索，可筛选出涉及该重组蛋白表达、功能或应用的最新原始研究论文。
**Background of FAM19A2 Recombinant Protein**
FAM19A2 (family with sequence similarity 19 member A2), also known as TAFA2 or S19A2. is a secreted protein belonging to the FAM19A family of cysteine-rich chemokine-like proteins. It is encoded by the *FAM19A2* gene located on human chromosome 12. Structurally, FAM19A2 contains conserved cysteine residues forming a "chemokine-like fold," which is characteristic of proteins involved in intercellular signaling. While its precise biological functions remain under investigation, FAM19A2 is implicated in regulating immune responses, neurodevelopment, and disease pathogenesis.
Emerging studies suggest FAM19A2 acts as a ligand for G protein-coupled receptors (GPCRs), potentially modulating intracellular signaling pathways such as MAPK and Akt. It is highly expressed in the central nervous system (CNS), particularly in neurons and glial cells, and may play roles in neuroprotection, synaptic plasticity, or neuroinflammation. Dysregulation of FAM19A2 has been linked to neurodegenerative disorders (e.g., Alzheimer’s disease), brain injuries, and cancers like gliomas.
Recombinant FAM19A2 protein, produced via heterologous expression systems (e.g., mammalian or bacterial cells), enables functional studies by providing a purified, bioactive form. Researchers utilize it to explore receptor interactions, signaling mechanisms, and therapeutic potential. For instance, in vitro and preclinical models indicate its involvement in suppressing tumor growth or attenuating neuroinflammatory responses. However, its full pathophysiological relevance and clinical applications require further validation.
Overall, FAM19A2 represents a promising yet underexplored target for understanding CNS disorders, immune modulation, and cancer biology, with recombinant tools accelerating mechanistic and translational research.
×
